<?xml version="1.0" encoding="UTF-8"?>
<p>In September 2004, Merck removed Vioxx
 <sup>®</sup> from the world market and in April 2005, the coxib study led the American Committee to conclude about the Cardiovascular Risk and suspension of Pfizer’s Bextra
 <sup>®</sup> (valdecoxib). Celecoxib is marketed only with a black stripe indication and the adverse cardiovascular effects are explained in the package leaflet [
 <xref rid="B36-molecules-25-03726" ref-type="bibr">36</xref>].
</p>
